AU1256288A - Treatment of human viral infections by dsrna combined with viral inhibitors - Google Patents

Treatment of human viral infections by dsrna combined with viral inhibitors

Info

Publication number
AU1256288A
AU1256288A AU12562/88A AU1256288A AU1256288A AU 1256288 A AU1256288 A AU 1256288A AU 12562/88 A AU12562/88 A AU 12562/88A AU 1256288 A AU1256288 A AU 1256288A AU 1256288 A AU1256288 A AU 1256288A
Authority
AU
Australia
Prior art keywords
viral
dsrna
hiv
mismatched
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12562/88A
Other languages
English (en)
Inventor
William A. Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hem Research Inc
Original Assignee
Hem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hem Research Inc filed Critical Hem Research Inc
Publication of AU1256288A publication Critical patent/AU1256288A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AU12562/88A 1987-03-23 1988-03-02 Treatment of human viral infections by dsrna combined with viral inhibitors Abandoned AU1256288A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2882387A 1987-03-23 1987-03-23
US028823 1987-03-23
US07/125,097 US4950652A (en) 1987-03-23 1987-11-25 dsRNAs for combination therapy in the treatment of viral diseases
US125097 1987-11-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU16188/92A Division AU660673B2 (en) 1987-03-23 1992-05-12 Treatment of human viral infection by dsRNA combined with viral inhibitors

Publications (1)

Publication Number Publication Date
AU1256288A true AU1256288A (en) 1988-09-22

Family

ID=26704119

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12562/88A Abandoned AU1256288A (en) 1987-03-23 1988-03-02 Treatment of human viral infections by dsrna combined with viral inhibitors

Country Status (21)

Country Link
US (1) US4950652A (enExample)
EP (1) EP0286224B1 (enExample)
JP (1) JP2656938B2 (enExample)
KR (1) KR960013435B1 (enExample)
CN (1) CN1049357C (enExample)
AU (1) AU1256288A (enExample)
CA (1) CA1316832C (enExample)
DE (1) DE3876125T2 (enExample)
DK (1) DK156688A (enExample)
ES (1) ES2066782T3 (enExample)
FI (1) FI881305L (enExample)
GR (1) GR3006340T3 (enExample)
HU (1) HUT46542A (enExample)
IE (1) IE63823B1 (enExample)
IL (1) IL85646A (enExample)
NO (1) NO881246L (enExample)
NZ (1) NZ223868A (enExample)
OA (1) OA08724A (enExample)
PH (1) PH23333A (enExample)
PT (1) PT87039B (enExample)
RU (1) RU2016572C1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130206A (en) * 1980-07-07 2000-10-10 Hem Research, Inc. Treating viral infections associated with chronic fatigue with dsRNA
US9309574B1 (en) 1984-08-22 2016-04-12 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Molecular cloning of HIV-1 from immortalized cell lines
US5091374A (en) * 1987-07-17 1992-02-25 Hem Research Inc. Double-stranded RNA correction of abnormalities in circulating immune complexes and monocyte function
US5906980A (en) * 1987-07-17 1999-05-25 Hem Research Inc. Treatment of hepatitis with mismatched dsRNA
US5712257A (en) * 1987-08-12 1998-01-27 Hem Research, Inc. Topically active compositions of mismatched dsRNAs
US4963532A (en) * 1987-11-25 1990-10-16 Hem Research, Inc. dsRNA-based prevention of viral escape
US4960592A (en) * 1989-04-17 1990-10-02 Lanocare Laboratories Lanolin and lanolin oil skin treatment composition
US5132292A (en) * 1990-05-25 1992-07-21 Hem Research, Inc. Treatment of viral hepatitis
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
GB9108085D0 (en) * 1991-04-16 1991-06-05 Scras Complexes of polyadenylic acid with polyuridylic acid
EP0581906A4 (en) * 1991-04-16 1997-07-23 Hem Pharma Corp Abrogation of viral resistance to nucleoside analogues by double-stranded rnas
CA2113573A1 (en) * 1991-07-16 1993-02-04 William Carter Modulation and diagnosis of cytokine dysfunctions
US20030207813A1 (en) * 1996-12-09 2003-11-06 G.D. Searle Retroviral protease inhibitor combinations
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
CN1192688A (zh) 1995-06-07 1998-09-09 特莱默里斯公司 联合疗法治疗hiv和其它病毒性感染
US5834443A (en) * 1996-05-21 1998-11-10 Masiello; Domenick J. Composition and method for treating herpes simplex
RU2123339C1 (ru) * 1996-06-18 1998-12-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Противовирусное средство
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
WO1998030223A1 (en) * 1997-01-17 1998-07-16 Icn Pharmaceuticals, Inc. Cytokine related treatments of disease
LT4475B (lt) * 1997-02-28 1999-02-25 Virmantas Stunžėnas Informacinės ribonukleino rūgšties panaudojimas vaistinėse medžiagose, skirtose padidinti šios ribonukleino rūgšties koduojamo baltymo kiekį paciento ląstelėse
FR2768344B1 (fr) * 1997-08-26 2001-02-16 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
FR2766715B1 (fr) * 1997-08-04 2001-02-16 Scras Produit comprenant au moins de l'arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique simultanee, separee ou etalee dans le temps, dans le traitement d'une maladie virale
FR2768345B1 (fr) * 1997-09-17 2001-05-04 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale, notamment d'une hepatite virale
FR2766711B1 (fr) * 1997-08-04 2001-02-02 Sod Conseils Rech Applic Produit comprenant au moins un arn double brin en association avec au moins un devire du 6-benzyluracile pour une utilisation therapeutique simultanee, separee ou etalee dans le temps
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CN101818145A (zh) 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
FR2776927B1 (fr) * 1998-04-07 2002-07-05 Univ Paris Curie Compositions pour la vectorisation de molecules
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
RU2172631C2 (ru) * 1999-10-08 2001-08-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Индуктор интерферона пролонгированного действия
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US20080242627A1 (en) * 2000-08-02 2008-10-02 University Of Southern California Novel rna interference methods using dna-rna duplex constructs
DE10100588A1 (de) * 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
EP1494684A2 (en) * 2001-12-14 2005-01-12 Hemispherx Biopharma USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
EP1478656B1 (en) 2002-02-01 2009-09-16 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
NZ535952A (en) 2002-04-04 2009-01-31 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US20050137154A1 (en) * 2003-05-16 2005-06-23 Hemispherx Biopharma Treating server acute respiratory syndrome
US20060035859A1 (en) * 2003-05-16 2006-02-16 Hemispherx Biopharma Treating severe and acute viral infections
US20050113292A1 (en) * 2003-07-18 2005-05-26 Vanderbilt University Compositions of protein mimetics and methods of using same against HIV-1, SARS-coV and the like
AU2004263037B2 (en) * 2003-08-11 2011-02-10 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Novel vaccine containing adjuvant capable of inducing mucosal immunity
RU2272631C2 (ru) * 2004-04-20 2006-03-27 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") Синергическая композиция для ингибирования вич
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
WO2007062107A2 (en) 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
US8075877B2 (en) 2006-03-08 2011-12-13 Hemispherx Biopharma Broad spectrum immune and antiviral gene modulation by oral interferon
CA2644670A1 (en) * 2006-03-08 2008-05-08 Hemispherx Biopharma Inc. Broad spectrum immune and antiviral gene modulation by oral interferon
EP2214668A1 (en) * 2007-10-29 2010-08-11 Cipla Limited Novel antiretroviral combination
NZ587371A (en) * 2008-02-15 2012-12-21 Hemispherx Biopharma Inc The use of poly(I:C11-14U) for treating bacterial and protozoan infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113162B1 (en) * 1982-09-16 1989-07-19 Hem Research, Inc. Anti-proliferative action of dsnras on tumor cells
NZ215486A (en) * 1985-03-16 1988-09-29 Wellcome Found 3'-azido-3'-deoxythymidine antiretroviral compositions (zidovudine, azt)
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4795744A (en) * 1986-07-17 1989-01-03 Hem Research, Inc. Modulation of AIDS virus-related events by double-stranded RNAS
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)

Also Published As

Publication number Publication date
DE3876125T2 (de) 1993-06-09
FI881305A7 (fi) 1988-09-24
RU2016572C1 (ru) 1994-07-30
GR3006340T3 (enExample) 1993-06-21
IE880839L (en) 1988-09-23
NO881246D0 (no) 1988-03-21
CA1316832C (en) 1993-04-27
JP2656938B2 (ja) 1997-09-24
FI881305L (fi) 1988-09-24
FI881305A0 (fi) 1988-03-18
OA08724A (fr) 1989-03-31
NO881246L (no) 1988-09-26
IE63823B1 (en) 1995-06-14
JPS6425A (en) 1989-01-05
KR960013435B1 (ko) 1996-10-05
HUT46542A (en) 1988-11-28
IL85646A (en) 1993-05-13
ES2066782T3 (es) 1995-03-16
PT87039B (pt) 1992-11-30
DK156688A (da) 1988-09-24
EP0286224B1 (en) 1992-11-25
CN88101606A (zh) 1988-12-28
EP0286224A3 (en) 1988-12-07
DE3876125D1 (de) 1993-01-07
PH23333A (en) 1989-07-14
US4950652A (en) 1990-08-21
IL85646A0 (en) 1988-08-31
KR880010777A (ko) 1988-10-24
DK156688D0 (da) 1988-03-22
CN1049357C (zh) 2000-02-16
PT87039A (pt) 1988-04-01
EP0286224A2 (en) 1988-10-12
NZ223868A (en) 1991-02-26

Similar Documents

Publication Publication Date Title
PH23333A (en) Treatment of human viral infections by dsrna combined with viral inhibitors
AU597635B2 (en) Treatment of diseases caused by retroviruses
AU577020B2 (en) Improvements relating to the treatment of tobacco
AU600264B2 (en) Treatment of fungal infections
AU1676588A (en) Treatment of materials
AU1811788A (en) Promotion of healing of meniscal tissue
ZW22687A1 (en) Treatment of diseases caused by viruses
GB8706872D0 (en) Prophylactic/therapeutic treatment of bacterial infections
ZA90245B (en) Treatment of diseases associated with hiv infections
PT88684A (pt) Metodo de tratamento fosfatidilico de doencas virais
AU1427188A (en) Elastic bandage
ZA835360B (en) Use of sugar derivatives for the prophylaxis and treatment of virus infections
AU7535681A (en) Treatment of infections
AU1618892A (en) Treatment of human viral infection by dsrna combined with viral inhibitors
AU588493B2 (en) Treatment of diseases caused by viruses
AU557033B2 (en) Treatment of warts
NO173145C (no) Fremgangsmaate for behandling av voerter
AU1678188A (en) Post harvest treatment of produce
GB8700950D0 (en) Treatment of super-alloy surfaces
AU6532886A (en) treatment of crops
AU7398587A (en) Treatment of soybeans
IE880770L (en) Treatment of viral infections
IE871465L (en) Treatment of bacterial infections
AU2795289A (en) Method of combating viral infections
IE892991L (en) Treatment of viral infections